Loading
Reading chemical marks on DNA and its packaging from 1 mL of blood let researchers infer which genes advanced cancers had switched on, including the targets of some drugs.
An immunoprecipitation-based method targeting histone modifications and DNA methylation measured 1,268 epigenomic profiles in plasma from 433 people with one of 15 cancers. It served as a proxy for transcriptional activity, inferring expression of diagnostic markers and drug targets, the activity of targetable transcription factors, and epigenetic mechanisms of resistance.
Blood can show what a tumour is doing, not only what mutations it has. It is a proof of concept in advanced cancer.
Shares Cell-free DNA (cfDNA), Nature Medicine, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Plasma epigenomic profiling (cfChIP-seq), Cell-free DNA (cfDNA).
Shares Plasma epigenomic profiling (cfChIP-seq), Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Cell-free DNA (cfDNA), Nature Medicine, Circulating tumour DNA (ctDNA).
Shares Cell-free DNA (cfDNA), Nature Medicine, Circulating tumour DNA (ctDNA).
Shares Cell-free DNA (cfDNA), Nature Medicine, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Plasma epigenomic profiling (cfChIP-seq), Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/